Daily Respiratory Research Analysis
Three impactful studies advance respiratory science and care: (1) SARS-CoV-2 directly drives neutrophils toward an immunosuppressive PMN-MDSC phenotype via LOX-1 upregulation and degranulation, illuminating mechanisms of severe COVID-19. (2) Dynamic oxygenation trajectories in ARDS outperform static PaO2/FiO2 in predicting outcomes and PEEP response, supporting time-aware phenotyping. (3) A nationwide cohort shows continued home NIV in COPD reduces mortality transitions.
Summary
Three impactful studies advance respiratory science and care: (1) SARS-CoV-2 directly drives neutrophils toward an immunosuppressive PMN-MDSC phenotype via LOX-1 upregulation and degranulation, illuminating mechanisms of severe COVID-19. (2) Dynamic oxygenation trajectories in ARDS outperform static PaO2/FiO2 in predicting outcomes and PEEP response, supporting time-aware phenotyping. (3) A nationwide cohort shows continued home NIV in COPD reduces mortality transitions.
Research Themes
- Immune dysregulation and myeloid remodeling in severe COVID-19
- Dynamic phenotyping and ventilatory management in ARDS
- Real-world outcomes of domiciliary noninvasive ventilation in COPD
Selected Articles
1. SARS-CoV-2 induces neutrophil degranulation and differentiation into myeloid-derived suppressor cells associated with severe COVID-19.
Hospitalized COVID-19 patients exhibit neutrophil degranulation with increased LOX-1 and PD-L1, features of PMN-MDSCs linked to severe disease. SARS-CoV-2 directly and rapidly induces LOX-1 on healthy neutrophils independent of productive infection via granule exocytosis, promoting an immunosuppressive, oxidative phenotype.
Impact: This study reveals a direct mechanism by which SARS-CoV-2 reprograms neutrophils into PMN-MDSCs, offering mechanistic insight into immune dysregulation in severe COVID-19 and nominating LOX-1/PD-L1 as actionable biomarkers.
Clinical Implications: LOX-1 and PD-L1 on neutrophils could serve as early biomarkers for risk stratification in COVID-19. Targeting neutrophil degranulation pathways or LOX-1 signaling may represent novel therapeutic strategies to mitigate immune dysregulation.
Key Findings
- Neutrophil degranulation and increased LOX-1/PD-L1 expression were observed in hospitalized COVID-19 patients and associated with severe disease.
- SARS-CoV-2 directly induced LOX-1 on healthy neutrophils independent of productive infection.
- LOX-1 induction required granule exocytosis and increased reactive oxygen species, CD63, and PD-L1, consistent with PMN-MDSC differentiation.
Methodological Strengths
- Combined patient immunophenotyping with mechanistic ex vivo experiments using healthy donor neutrophils.
- Clear linkage between a defined cellular process (granule exocytosis) and immunosuppressive phenotype induction.
Limitations
- Sample sizes and full quantitative patient cohort details are not provided in the abstract.
- Findings are mechanistic and require interventional validation to confirm therapeutic tractability in vivo.
Future Directions: Prospective studies validating neutrophil LOX-1/PD-L1 as prognostic biomarkers, and interventional trials targeting LOX-1 signaling or degranulation pathways in severe COVID-19.
Severe COVID-19 presents with a distinct immunological profile, characterized by elevated neutrophil and reduced lymphocyte counts, seen commonly in fungal and bacterial infections. This study demonstrates that patients hospitalized with COVID-19 show evidence of neutrophil degranulation and have increased expression of neutrophil surface lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), a marker of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Both early LOX-1 and programmed death-ligand 1 (PD-L1) expression on neutrophils were associated with development of severe disease. To determine whether tissue damage or inflammation is required to induce PMN-MDSCs or whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly activates neutrophils to become PMN-MDSCs, we incubated healthy human neutrophils with SARS-CoV-2. SARS-CoV-2 rapidly induced LOX-1 surface expression in healthy neutrophils independent of productive infection. LOX-1 induction was dependent on granule exocytosis and promoted up-regulation of reactive oxygen species, CD63, and PD-L1, enabling LOX-1
2. Impact of long-term non-invasive ventilation on severe exacerbations and survival in COPD: a French nationwide cohort study using multistate models.
In 49,503 COPD patients initiated on home NIV, continued NIV significantly reduced transitions to death from both non-exacerbation and severe exacerbation states, without reducing transitions into severe exacerbations. These nationwide data support mortality benefit from sustained domiciliary NIV.
Impact: This is the largest real-world analysis demonstrating mortality-related benefits of continuing domiciliary NIV in COPD using robust multistate modeling, informing guideline and reimbursement policy.
Clinical Implications: For COPD patients on home NIV, continuation should be prioritized given the association with reduced mortality transitions. NIV may not reduce severe exacerbation incidence but can improve survival pathways; adherence support and persistence strategies are warranted.
Key Findings
- Among 49,503 COPD patients, continued home NIV reduced transitions to death from both non-exacerbation (HR 0.88) and severe exacerbation states (HR 0.84).
- NIV continuation did not significantly change the transition from non-exacerbation to severe exacerbation (HR 0.98).
- There were 80,361 severe exacerbations and 18,125 deaths, enabling robust multistate modeling of disease trajectories.
Methodological Strengths
- Very large nationwide cohort with 49,503 NIV users and comprehensive event capture.
- Use of multistate models to assess transitions between clinically meaningful disease states.
Limitations
- Observational design with potential for confounding by indication and unmeasured adherence effects.
- Administrative data lack granular physiologic parameters to contextualize NIV settings or gas exchange.
Future Directions: Prospective pragmatic trials and registry-based studies integrating NIV adherence, settings, and physiologic data to refine patient selection and quantify causal effects on survival.
RATIONALE: Chronic obstructive pulmonary disease (COPD) is the most common indication for domiciliary non-invasive ventilation (NIV), but long-term outcomes data are limited. OBJECTIVE: This multistate model analysis estimated the impact of NIV therapy continuation versus cessation on transitions between three different disease states. METHODS: Model data came from the French national health insurance reimbursement system database for individuals aged ≥40 years with COPD and ≥1 NIV reimbursement in 2015-2019. MEASUREMENT AND MAIN RESULTS: Data from 49 503 patients started on NIV were included (median age 70 years, 51.2% male, median 1 exacerbation in the previous year). There were 80 361 severe exacerbations and 18 125 deaths (including 7805 in severe exacerbation). In multistate models, NIV continuation was associated with a significant reduction in transition to death, from severe exacerbation (HR 0.84, 95% CI 0.79 to 0.91) and without exacerbation (HR 0.88, 95% CI 0.83 to 0.93). NIV continuation versus cessation had no significant effect on transition between without exacerbation to severe exacerbation (HR 0.98, 95% CI 0.95 to 1.00) but was significantly associated with slower transition from severe exacerbation to without exacerbation (HR 0.87, 95% CI 0.84 to 0.89). CONCLUSION: This multistate model analysis found that the long-term use of domiciliary NIV was associated with a lower risk of transitions to death, but was not associated with a reduction in recovery time after severe exacerbation. These data highlight the potential mortality benefits of long-term domiciliary NIV in COPD and can be used as one piece of evidence to support evidence-based guideline recommendations.
3. Dynamic oxygenation subgroup bringing new insights in ARDS: more predictive of outcomes and response to PEEP than static PaO2/FiO2.
Using five ARDS datasets (n=814 training; n=2505 validation), three PaO2/FiO2 trajectory subgroups over the first 3 days outperformed static Berlin categories in predicting outcomes and PEEP responsiveness. Dynamic oxygenation phenotyping captures disease evolution and improves prognostication.
Impact: Introduces validated, time-aware ARDS phenotypes with superior predictive performance over static PaO2/FiO2 classification, offering a path toward precision ventilatory management.
Clinical Implications: Tracking early oxygenation trajectories can inform risk stratification and PEEP titration beyond static PaO2/FiO2 thresholds. Integrating trajectory-based phenotyping into ICU workflows and trials may enhance individualized ARDS care.
Key Findings
- Three PaO2/FiO2 trajectory subgroups over the first 3 days post-ARDS diagnosis were derived and validated across five datasets.
- Dynamic subgroups were more predictive of outcomes and PEEP responsiveness than static Berlin categories.
- Validation across multiple cohorts (FACTT, SAILS, ALVEOLI, MIMIC-IV) supports generalizability.
Methodological Strengths
- Group-based trajectory modeling with external validation across multiple, well-characterized ARDS cohorts.
- Direct comparison with Berlin criteria and assessment of PEEP responsiveness.
Limitations
- Retrospective analyses may be subject to missing data and residual confounding.
- Trajectory application requires frequent early arterial blood gas data, which may limit implementation in some settings.
Future Directions: Prospective trials to test trajectory-guided ventilator strategies (e.g., PEEP titration) and integration of additional physiologic signals to refine dynamic phenotypes.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a rapidly evolving condition. Dynamic assessments using patient trajectories may provide novel insights into disease heterogeneity. The primary objective of this study was to develop and validate dynamic oxygenation subgroups of ARDS based on longitudinal arterial oxygen tension/fractional inspired oxygen (PaO METHODS: We used group-based trajectory modelling to construct longitudinal oxygenation subgroups over the first 3 days following ARDS diagnosis, based on five ARDS databases. Additionally, we compared these longitudinal subgroups with static Berlin criteria-defined mild, moderate and severe subgroups in terms of clinical characteristics, outcomes and positive end-expiratory pressure (PEEP) responses. RESULTS: A total of 814 and 2505 patients with ARDS were included in the training cohort (Chinese ARDS Database) and validation cohorts (FACTT, SAILS, ALVEOLI and MIMIC-IV), respectively. We derived three longitudinal oxygenation subgroups: group 1 (n=406, 49.88%), group 2 (n=302, 37.10%) and group 3 (n=106, 13.02%). The PaO CONCLUSIONS: We identified three longitudinal oxygenation subgroups of ARDS that were more predictive of prognosis and response to PEEP than the subgroups defined by static PaO